Search results for "Agent"

showing 10 items of 8904 documents

Tolerating malicious monitors in detecting misbehaving robots

2008

This paper considers a multi–agent system and focuses on the detection of motion misbehavior. Previous work by the authors proposed a solution, where agents act as local monitors of their neighbors and use locally sensed information as well as data received from other monitors. In this work, we consider possible failure of monitors that may send incorrect information to their neighbors due to spontaneous or even malicious malfunctioning. In this context, we propose a distributed software architecture that is able to tolerate such failures. Effectiveness of the proposed solution is shown through preliminary simulation results.

0209 industrial biotechnologybusiness.industryComputer scienceDistributed computing020206 networking & telecommunicationsContext (language use)security02 engineering and technologyMotion (physics)consensus algorithm020901 industrial engineering & automationSettore ING-INF/04 - AutomaticaWork (electrical)Embedded system0202 electrical engineering electronic engineering information engineeringRobotDistributed software architectureIntrusion detectionmulti-agent systemsSoftware architecturebusiness
researchProduct

Ensuring the Reliability of an Autonomous Vehicle

2017

International audience; In automotive applications, several components, offering different services, can be composed in order to handle one specific task (autonomous driving for example). Nevertheless, component composition is not straightforward and is subject to the occurrence ofbugs resulting from components or services incompatibilities for instance. Hence, bugs detection in component-based systems at thedesign level is very important, particularly, when the developed system concerns automotive applications supporting critical services.In this paper, we propose a formal approach for modeling and verifying the reliability of an autonomous vehicle system, communicatingcontinuously with of…

021110 strategic defence & security studiesFocus (computing)021103 operations researchComputer sciencebusiness.industryDistributed computingReliability (computer networking)0211 other engineering and technologiesAutomotive industry[INFO.INFO-SE]Computer Science [cs]/Software Engineering [cs.SE]02 engineering and technology[INFO.INFO-MO]Computer Science [cs]/Modeling and SimulationTask (project management)[INFO.INFO-IU]Computer Science [cs]/Ubiquitous Computing[INFO.INFO-CR]Computer Science [cs]/Cryptography and Security [cs.CR][INFO.INFO-MA]Computer Science [cs]/Multiagent Systems [cs.MA]Systems Modeling LanguageComponent (UML)Systems architectureTime constraint[INFO.INFO-ET]Computer Science [cs]/Emerging Technologies [cs.ET][INFO.INFO-DC]Computer Science [cs]/Distributed Parallel and Cluster Computing [cs.DC]businessProceedings of the 20th ACM International Conference on Modelling, Analysis and Simulation of Wireless and Mobile Systems
researchProduct

Investigation of Isoindolo[2,1-a] quinoxaline-6-imines as Topoisomerase I Inhibitors with Molecular Modeling Methods

2017

Background: Isoindolo[2,1-alpha] quinoxalines constitute an important class of compounds which demonstrated potent antiproliferative activity against different human tumor cell lines and topoisomerase I inhibitors. In particular, their water soluble imine or iminium salts recently synthesized showed potent growth inhibitory effect on NCI-60 tumor cell line panel and biological studies performed on the most active compounds demonstrated that they cause DNA damage via topoisomerase I poisoning. Objective: Herein, we investigate with molecular modeling methods, the common features responsible for topoisomerase I inhibition of the water-soluble isoindolo[2,1-alpha] quinoxalin-6-imines, by compa…

0301 basic medicine030103 biophysicsMolecular modelStereochemistryDNA damageAntineoplastic AgentsIsoindolesTopoisomerase-I InhibitorCrystallography X-RayaromatechinStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundQuinoxalinetopotecanantiproliferativeCell Line TumorNeoplasmsQuinoxalinesquinoxalineDrug DiscoveryHumansCell Proliferationbiologypharmacophore modelTopoisomeraseIminiumGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaMolecular Docking SimulationTopoisomerase IindenoisoquinolineDNA Topoisomerases Type IchemistryDocking (molecular)dockingbiology.proteinMolecular MedicineTopoisomerase I; quinoxaline; antiproliferative; topotecan; aromatechin; indenoisoquinoline; docking; pharmacophore modelIminesTopoisomerase I InhibitorsPharmacophore
researchProduct

Effect of in-office bleaching gels with calcium or fluoride on color, roughness, and enamel microhardness

2019

Background Commercial bleaching gels with remineralizing agents were developed to reduce the adverse effects of dental bleaching. The present study evaluated the effects on teeth of in-office bleaching gels containing 35-40% hydrogen peroxide (HP) with Calcium (Ca) or Fluoride (F). Material and methods Bovine enamel/dentin blocks (4x4x2.5 mm) were randomly divided into the following groups (n=12): no treatment (control); 35% HP (Whiteness HP, FGM); 35% HP with Ca (Whiteness HP Blue, FGM); 40% HP with F (Opalescence Boost, Ultradent). The specimens were analyzed for color (ΔL*, Δa*, Δb*, and ΔE), roughness (Ra), and Knoop microhardness (KHN). The color and KHN data were submitted to ANOVA an…

0301 basic medicine030103 biophysicsgenetic structureschemistry.chemical_elementCalcium03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOpalescenceDentinmedicineHydrogen peroxideGeneral DentistryTooth Bleaching AgentsEnamel paintResearch030206 dentistryEsthetic Dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.anatomical_structurechemistryvisual_artUNESCO::CIENCIAS MÉDICASvisual_art.visual_art_mediumKnoop hardness testFluorideNuclear chemistry
researchProduct

Constitutive activation of MexT by amino acid substitutions results in MexEF-OprN overproduction in clinical isolates of Pseudomonas aeruginosa

2018

ABSTRACT When overproduced, the multidrug efflux system MexEF-OprN increases the resistance of Pseudomonas aeruginosa to fluoroquinolones, chloramphenicol, and trimethoprim. In this work, we demonstrate that gain-of-function mutations in the regulatory gene mexT result in oligomerization of the LysR regulator MexT, constitutive upregulation of the efflux pump, and increased resistance in clinical isolates.

0301 basic medicine030106 microbiologyMicrobial Sensitivity Tests[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologymedicine.disease_causeMicrobiology03 medical and health sciencesAntibiotic resistanceDownregulation and upregulationMechanisms of Resistance[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance BacterialmedicinePharmacology (medical)OverproductionComputingMilieux_MISCELLANEOUSRegulator genePharmacologychemistry.chemical_classificationChemistryPseudomonas aeruginosaChloramphenicolGene Expression Regulation Bacterial[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good healthAmino acidAnti-Bacterial AgentsInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAmino Acid SubstitutionMutationPseudomonas aeruginosaEffluxmedicine.drug
researchProduct

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

2,3-Dihydrobenzofuran privileged structures as new bioinspired lead compounds for the design of mPGES-1 inhibitors

2016

International audience; 2,3-Dihydrobenzofurans are proposed as privileged structures and used as chemical platform to design small compound libraries. By combining molecular docking calculations and experimental verification of biochemical interference, we selected some potential inhibitors of microsomal prostaglandin E2 synthase (mPGES)-1. Starting from low affinity natural product 1, by our combined approach we identified the compounds 19 and 20 with biological activity in the low micromolar range. Our data suggest that the 2,3-dihydrobenzofuran derivatives might be suitable bioinspired lead compounds for development of new generation mPGES-1 inhibitors with increased affinity.

0301 basic medicine300323-Dihydrobenzofuran privileged structure; Cancer; Inflammation; Molecular docking; mPGES-1 inhibitors; Biochemistry; Clinical Biochemistry; Molecular Biology; Molecular Medicine; Organic Chemistry; Drug Discovery3003 Pharmaceutical Science; 3003Amino Acid MotifsClinical BiochemistryGene ExpressionPharmaceutical Science01 natural sciencesClinical biochemistryBiochemistry[ CHIM ] Chemical SciencesProtein Structure Secondary[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compoundLow affinityDrug DiscoveryEnzyme Inhibitors23-Dihydrobenzofuran privileged structure; Molecular docking; mPGES-1 inhibitors; Cancer; InflammationProstaglandin-E SynthasesCancerAnti-Inflammatory Agents Non-SteroidalBiological activityProto-Oncogene Proteins c-metIntramolecular OxidoreductasesMolecular Docking SimulationMolecular dockingMolecular Medicinelipids (amino acids peptides and proteins)Cell SurvivalStereochemistryMolecular Sequence Data2Antineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer3-Dihydrobenzofuran privileged structureInhibitory Concentration 50Structure-Activity Relationship03 medical and health sciencesCell Line TumorMicrosomesHumans[CHIM]Chemical SciencesMolecular BiologyBenzofuransInflammationNatural product010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryEpithelial CellsmPGES-1 inhibitorsCombinatorial chemistryCombined approach0104 chemical sciences030104 developmental biologychemistryDrug DesignDrug Screening Assays Antitumor
researchProduct

Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment

2018

Standard of care for cancer is commonly a combination of surgery with radiotherapy or chemoradiotherapy. However, in some advanced cancer patients this approach might still remaininefficient and may cause many side effects, including severe complications and even death. Oncolytic viruses exhibit different anti-cancer mechanisms compared with conventional therapies, allowing the possibility for improved effect in cancer therapy. Chemotherapeutics combined with oncolytic viruses exhibit stronger cytotoxic responses and oncolysis. Here, we have investigated the systemic delivery of the oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicles (EV) formulation that, in vitro, s…

0301 basic medicine3003Lung NeoplasmsCancer therapymedicine.medical_treatmentPharmaceutical ScienceOncolytic viruseschemistry.chemical_compoundpaclitaxelkeuhkosyöpä0302 clinical medicineMedicineMice Inbred BALB CExtracellular vesiclesCHEMOTHERAPYCombined Modality Therapy3. Good healthxenograft animal modelPaclitaxelLiver317 Pharmacy030220 oncology & carcinogenesisonkolyyttiset viruksetcancer therapyFemaleLung canceronkolyyttinen virushoitoOncolytic adenovirusEFFICIENCYPaclitaxelCancer therapy; Drug delivery; Extracellular vesicles; Lung cancer; Oncolytic viruses; Paclitaxel; Xenograft animal model; 30033122 CancersMice NudeXenograft animal modelta3111OVARIAN-CANCERVIROTHERAPY03 medical and health sciencesCell Line TumorAnimalsHumansVirotherapyLung cancerChemotherapyADENOVIRUS RECEPTORsyöpähoidotbusiness.industryta1182CancerENDOSTATINmedicine.diseaseta3122Antineoplastic Agents PhytogenicGENEOncolytic virusMODELlung cancer030104 developmental biologychemistryviroterapiaDrug deliveryCELLSdrug deliveryCancer researchbusinessOvarian cancersolunulkoiset vesikkelitSpleen
researchProduct

An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds

2017

The synthesis, the antitumor activity, the SAR and, whenever described, the possible mode of action of 1,2,4-triazine derivatives, their N-oxides, N,. N'-dioxides as well as the benzo- and hetero-fused systems are reported. Herein are treated derivatives disclosed to literature from the beginning of this century up to 2016. Among the three possible triazine isomers, 1,2,4-triazines are the most studied ones and many derivatives having remarkable antitumor activity have been reported in the literature and also patented reaching advanced phases of clinical trials.

0301 basic medicine4-benzotriazine124-triazineAntineoplastic AgentsChemistry Techniques SyntheticAntiproliferative activity01 natural sciences03 medical and health scienceschemistry.chemical_compoundNeoplasmsDrug DiscoveryOrganic chemistryAnimalsHumans124-triazineMode of action124-benzotriazineTriazineAntitumor activityPharmacology010405 organic chemistryChemistryTriazinesNitrogen heterocyclesDrug Discovery3003 Pharmaceutical Science1; 2; 4-benzotriazine; 1; 2; 4-triazine; Antiproliferative activity; Antitumor activity; Nitrogen heterocycles; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Organic ChemistryOrganic ChemistryGeneral MedicineCombinatorial chemistrySettore CHIM/08 - Chimica Farmaceutica0104 chemical sciences030104 developmental biologyNitrogen heterocycleDrug Screening Assays AntitumorAntitumor activity
researchProduct

Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer

2020

Hepatocellular carcinoma (HCC) represents 80% of the primary hepatic neoplasms. It is the sixth most frequent neoplasm, the fourth cause of cancer-related death, and 7% of registered malignancies. Sorafenib is the first line molecular targeted therapy for patients in advanced stage of HCC. The present study shows that Sorafenib exerts free radical scavenging properties associated with the downregulation of nuclear factor E2-related factor 2 (Nrf2)-regulated thioredoxin 1 (Trx1) expression in liver cancer cells. The experimental downregulation and/or overexpression strategies showed that Trx1 induced activation of nitric oxide synthase (NOS) type 3 (NOS3) and S-nitrosation (SNO) of CD95 rece…

0301 basic medicine:Anatomy::Cells::Cells Cultured::Cell Line::Cell Line Tumor [Medical Subject Headings]Factor 2 relacionado con NF-E2Regulación hacia abajomedicine.medical_treatment[SDV]Life Sciences [q-bio]Clinical Biochemistry:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Thioredoxins [Medical Subject Headings]ApoptosisBiochemistry:Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Nitrosation [Medical Subject Headings]Targeted therapyNeoplasias hepáticas:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Mice0302 clinical medicineThioredoxins:Organisms::Eukaryota::Animals [Medical Subject Headings]lcsh:QH301-705.5Cell proliferationlcsh:R5-920GSNORChemistry:Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [Medical Subject Headings]Liver NeoplasmsSorafenibFas receptor3. Good healthHepatocellular carcinomaCD95Liver cancerlcsh:Medicine (General)NOS3Liver cancerCarcinoma hepatocelularResearch Papermedicine.drugSorafenibHepatocarcinomaProliferación celularCarcinoma HepatocellularNitrosationDown-RegulationMice Nude[SDV.CAN]Life Sciences [q-bio]/CancerAntineoplastic AgentsNrf203 medical and health sciencesDownregulation and upregulationCell Line TumormedicineAnimalsHumansS-NitrosoglutatiónTiorredoxinas:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Growth Processes::Cell Proliferation [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings]:Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma Hepatocellular [Medical Subject Headings]:Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Down-Regulation [Medical Subject Headings]Cell growthPhenylurea CompoundsOrganic Chemistry:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings][SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice::Mice Mutant Strains::Mice Nude [Medical Subject Headings]medicine.diseasedigestive system diseases030104 developmental biologylcsh:Biology (General)ApoptosisDownregulation:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Benzene Derivatives::Phenylurea Compounds [Medical Subject Headings][SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyCancer researchÓxido nítrico sintasa de tipo III030217 neurology & neurosurgery
researchProduct